Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contact Us Login 
An Official Publication of the Indian Association of Oral and Maxillofacial Pathologists


 
  Table of Contents    
REVIEW ARTICLE  
Year : 2014  |  Volume : 18  |  Issue : 2  |  Page : 235-243
 

Uncommon opportunistic fungal infections of oral cavity: A review


Department of Oral and Maxillofacial Pathology, PMS College of Dental Science and Research, Vattappara, Thiruvananthapuram, Kerala, India

Date of Submission25-Feb-2014
Date of Acceptance04-Jul-2014
Date of Web Publication17-Sep-2014

Correspondence Address:
A G Deepa
Post Graduate Student, Department of Oral and Maxillofacial Pathology, PMS College of Dental Science and Research, Vencode P. O, Vattappara, Thiruvananthapuram, Kerala 695 028
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-029X.140765

Rights and Permissions

 

   Abstract 

The majority of opportunistic oral mucosal fungal infections are due to Candida albicans and Aspergillus fumigatus species. Mucor and Cryptococcus also have a major role in causing oral infections, whereas Geotrichum, Fusarium, Rhodotorula, Saccharomyces and Penicillium marneffei are uncommon pathogens in the oral cavity. The broad spectrum of clinical presentation includes pseudo-membranes, abscesses, ulcers, pustules and extensive tissue necrosis involving bone. This review discusses various uncommon opportunistic fungal infections affecting the oral cavity including their morphology, clinical features and diagnostic methods.


Keywords: Immunocompromised patients, opportunistic fungi, oral cavity


How to cite this article:
Deepa A G, Nair BJ, Sivakumar T T, Joseph AP. Uncommon opportunistic fungal infections of oral cavity: A review. J Oral Maxillofac Pathol 2014;18:235-43

How to cite this URL:
Deepa A G, Nair BJ, Sivakumar T T, Joseph AP. Uncommon opportunistic fungal infections of oral cavity: A review. J Oral Maxillofac Pathol [serial online] 2014 [cited 2019 Nov 20];18:235-43. Available from: http://www.jomfp.in/text.asp?2014/18/2/235/140765



   Introduction Top


Humans are exposed to hundreds of fungal spores daily, usually not producing any harmful effect on their health. This protection is by various pulmonary defense mechanisms that effectively eliminate the fungal spores. [1]

Coccidioides immitis, Histoplasma capsulatum, Blastomyces dermatitidis, Paracoccidioides brasiliensis and dermatophyte fungi can infect healthy, immunologically competent individuals. [1] By contrast, species such as Candida, Aspergillus, Rhizopus and Fusarium are normally avirulent in healthy people, but can cause disseminated fatal infections in patients with suppressed immunity. These are called opportunistic pathogenic fungi. The fungus Cryptococcus neoformans can be considered both as a true and opportunistic pathogen since it can cause infections in immunologically competent as well as immunocompromised hosts. [1]

The occurrence of superficial as well as invasive opportunistic fungal infections has increased significantly over the past two decades. This increase can be attributed to the growing number of immunocompromised patients- including those with AIDS, neoplastic disease, advanced age, long-standing diabetes mellitus, undergoing blood and marrow transplantation, solid-organ transplantation, major surgery, receiving immunosuppressive therapy and premature infants. [2] Genetic predisposition to invasive fungal infection has been reported recently owing to defective NADPH oxidase activity, abnormal production of tumor necrosis factor- α, interleukin 10 and other cytokines. [3],[4]

The spectrum of opportunistic fungal infections is changing. The majority of invasive fungal infections are still due to Aspergillus and Candida species; but infections due to mycelial fungi other than Aspergillus and non-albicans species of Candida are becoming increasingly common. [5] Any fungus present in the environment can be potentially pathogenic in immunocompromised patients. [6]

This review considers the main general and oral aspects of these emerging uncommon opportunistic fungal infections such as Candidiasis due to Candida species other than C. albicans, Aspergillosis due to non-fumigates species of Aspergillus, Mucormycosis, Cryptococcosis, Geotrichosis, Rhodotorula infection, Saccharomyces infection, Fusariosis and Penicilliosis.


   Candidiasis due to candida species other than c. Albicans Top


Oral candidiasis is the most common human fungal infection. [7] Even though C. albicans is the most common pathogen responsible for candidiasis, other Candida species causing oral infections have also been identified including C. glabrata, C. krusei, C. parapsilosis, C. dublieniesis, C. tropicalis, C. kefyr and C. guilliermondii. [8],[9],[10],[11] Less commonly isolated species are C. inconspicua, C. lusitaniae, C. norvegensis and C. rugosa. [12] These species are resistant to the commonly used azole antifungal drugs. [13] These non-Candida albicans Candida species lack many of the virulence factors present in the virulent C. albicans i.e.

the ability to form hyphae and phenotypic switching. They have low adherence capacity to buccal epithelial and vascular endothelial surfaces. They secrete less proteinases. Thus they are thought to cause candidiasis of less severity. [14]

C. dublieniesis is a species associated with oral lesions in HIV-infected individuals. It is morphologically and genotypically closely related to C. albicans. [15],[16] C. dublieniesis is the only Candida species other than Candida albicans that forms true hyphae. They show decreased susceptibility to fluconazole. [17]

C. glabrata is emerging as an important pathogen in both mucosal and blood stream infections and is commonly isolated from the oral cavity of HIV-infected individuals. [11],[14] C. glabrata-associated oropharyngeal candidiasis in HIV infection and cancer patients is more severe and more difficult to treat due to their quick development of resistance to fluconazole. [18]

C. guilliermondii cause infection in patients undergoing surgical procedures, endocarditis, in intravenous drug users and fungemia in immunocompromised patients. [19] They show resistance to amphotericin B. [20]

C. krusei infection occurs in critically ill patients mainly in hematology patients with severe neutropenia. It is an uncommon pathogen causing candidemia. The increase in C. krusei infection in HIV-infected patients is thought to be due to the widespread use of fluconazole prophylaxis. [21]

C. lusitaniae mainly causes infection in immunocompromised hosts with prolonged antibiotic administration, hospitalization, cytotoxic or corticosteroid treatment, granulocytopenia and low-birthweight babies. [22],[23]

C. parapsilosis mainly affects critically ill neonates and patients in intensive care units i.e. prematurity and low birth weight are recognized as the risk factors. [24]

C. tropicalis is the most virulent of the non-albicans Candida species. This may be due to its ability to adhere to epithelial cells in vitro and to secrete moderate levels of proteinases. [14] It is usually isolated from oral cavity and skin and can cause infections in esophagus in patients with systemic diseases. [25]

Diagnosis

The diagnosis of candidiasis is often made on the basis of clinical suspicion of the typical mucosal changes and angular cheilitis. These are almost always associated with some degree of discomfort. [26] Microscopic examination of the smears stained with periodic acid Schiff's method (PAS), or KOH preparation can reveal candidal hyphae and blastospores. [27]

Qualitation is accomplished by culture on Sabouraud's dextrose agar (SDA) at 25-30ºC for 48-72 hours. [28] Germ tube growth can be used for identification of C. albicans whereas carbohydrate assimilations can be employed for other species. [26] Culture on CHROMagar can be used to identify C. albicans, C. krusei and C. tropicalis. C. albicans forms green colonies, C. krusei form fuzzy, rose-colored colonies and C. tropicalis show steel-blue colonies. [13],[29],[30] CHROMagar-PAL is a new method which combines CHROMagar Candida and Pal agar that can easily differentiate between C. albicans and C. dublieniesis even in mixed cultures. ELISA and polymerase chain reaction (PCR) may also be used for the same. Multiplex PCR, which identifies yeast directly in clinical samples is a more recent advancement. [31] Further speciation can be done by conventional biotyping techniques or with the aid of commercially available systems like Micronaut-Candida, API ID32C, RapID yeast plus system, Auxocolor, Vitek, Api Candida, etc. [32],[33] Quantitation is done by collecting whole saliva and plating on SDA, incubating and counting the colony-forming units. [28]

Biopsy is mainly done to rule out hyperplastic candidiasis. In hyperplastic candidiasis, histopathological examination will reveal epithelial parakeratosis with polymorphonuclear leukocytes in the superficial layers. PAS-staining will show the presence of Candidal hyphae in these areas. [34]


   Aspergillosis Top


Aspergillosis has been reported as the second most prevalent opportunistic fungal infection. [35] Aspergillus species are universally found in humid areas, damp soil, grain, cereal, mouldy flour and organic decaying or decomposing matter. [36] In the hospital setting, construction activities, rotten leaves or insufficient cleaning of dust can increase the risk of developing aspergillosis. [37] Aspergillus fumigatus is the most familiar pathogen of the species. Human infections are also caused by less common Aspergillus species, such as Aspergillus flavus, Aspergillus glaucis, Aspergillus terrus, Aspergillus parasiticus, Aspergillus repens, Aspergillus nidulans, Aspergillus niger and Aspergillus tubingensis. [38],[39] In India, the most common species encountered is A. flavus followed by Aspergillus fumigatus and A. niger. [40]

Rowe Jones in 1994 classified aspergillosis into three chief variants: Invasive, non-invasive and non-invasive destructive type. Invasive type represents true fungal tissue invasion that can be either slow progressive and destructive (non-fulminant) or highly aggressive and lethal (fulminant). Non-invasive type is further classified into Aspergilloma, Fungal ball, Mycetoma (usually affecting one sinus) or allergic Aspergillus sinusitis (involving more than one sinus). Destructive non-invasive variant is locally destructive but shows no tissue invasion. [41]

Clinical presentation

Aspergillosis generally occurs after inhalation of spores, that can result in both upper and lower respiratory tract infection- bronchopulmonary aspergillosis. [42] From lungs, infections may spread to the brain, bone or endocardium. [43] Paranasal sinuses, larynx, eyes, ears and the oral cavity may be involved in primary aspergillosis. [43],[44] A. fumigatus is the usual agent of sinus aspergillosis, whereas A. flavus is more common in invasive lesions in immunosuppressed individuals. [45] Orofacial aspergillosis is relatively common in patients undergoing treatment for malignancies of the blood and blood-forming organs. [44],[46],[47],[48]

Aspergillus does not contain chlorophyll, thus light is not required for growth. Aspergillus exhibits a centrifugal linear growth unless inhibited by natural or artificial barriers. This is why Aspergillus in the paranasal sinus eventually develops into a ball-shaped mass. [49] The centre of the mass contains calcium phosphate and therefore mimics a foreign body on radiography. [50]

In most cases, oral aspergillosis lesions are yellow or black in color, with a necrotic ulcerated base, classically located on the palate or posterior tongue. [46],[51] Aspergillus hyphae invade host tissues through the release of various toxins. These include various proteases, phospholipases, hemolysins, gliotoxin, aflatoxin, phthioic acid and other toxins. [52] The hyphal elements of the fungus may invade the oral mucosa and penetrate the walls of small to medium-sized blood vessels, producing thrombosis, infarction and necrosis, finally leading to systemic spread. [53]

Diagnosis

Histopathologically, invasive lesions show chronic granulomatous reactions. In hematoxylin and eosin-stained sections hyphal forms can be seen faintly in the center of an area of necrosis. They may go unnoticed unless special stains like methanamine silver are used. The fungi appear as septate hyphae, showing branching at 45° angles and are about 2-4 mm in diameter. [54] Conidiospores and fruiting bodies are also seen. This fungus should be differentiated from mucor which shows broader non-septate hyphae with branching at 90°. [55],[56]


   Mucormycosis Top


Mucormycosis (Zygomycosis or Phycomycosis) is an opportunistic mycotic infection caused by Mucorales. [57] It is considered as the third most common opportunistic fungal infection after candidiasis and aspergillosis. [58] The common genera causing disease are Rhizopus, Rhizomucor and Absidia. Rhizopus is the chief pathogen accounting for 90% of the cases of rhinocerebral mucormycosis. [59]

This fungus is widespread in soil, manure, vegetables and as bread mould. [60] This pathogen may be cultured from the oral cavity, nasal passages, throat and stool of healthy patients without clinical signs of infection. [59] The infection usually results from inhalation of fungal spores, contamination of traumatized tissue, ingestion or direct inoculation. [61] An area of ulceration or an extraction socket in the mouth can be a port of entry for mucormycosis into the maxillofacial region, chiefly when the patient is immunocompromised. [62]

Up to 40-50% of patients suffering from mucormycosis have diabetes mellitus (DM). [63],[64] Acidosis in DM reduce the phagocytic ability of granulocytes thereby affecting the immunological capability to resist mucormycosis. [65],[66] During the state of diabetic ketoacidosis, the acidic environment and the increase in the levels of free ferric ions support the growth of mucorales. [67] In diabetic patients there is a high occurrence of mucormycosis caused by Rhizopus oryzae, because they produce the enzyme ketoreductase, which enables them to make use of the patient's ketone bodies. [68]

Mucorales have the ability to damage and penetrate endothelial lining of blood vessels. This accounts for the most characteristic feature of mucormycosis i.e. widespread angioinvasion resulting in thrombosis and tissue necrosis. [69]

Clinical presentation

Eisenberg et al. described six clinical variants- rhinocerebral (rhinomaxillary), pulmonary, cutaneous, gastrointestinal, central nervous system and disseminated type. [68] Rhinocerebral form is the most common clinical variant which has been further divided into two subtypes: (i) A highly fatal rhino-orbito-cerebral form which is invasive involving the ophthalmic and internal carotid arteries, (ii) A less fatal rhino-maxillary form which involves the sphenopalatine and greater palatine arteries, resulting in thrombosis of the turbinate and necrosis of the palate. [59],[70],[71]

The clinical presentation of rhinocerebral mucormycosis includes malaise, headache, facial pain, swelling an irregular black eschar, exudation of pus from the eye and nose and low-grade fever. [64] The disease usually starts in the nasal mucosa or palate and spread through the surrounding vessels to the paranasal sinuses, frequently involving maxillary and ethmoid sinuses. In addition, mucormycosis can involve the retro-orbital region by direct extension. [61],[63],[72] Orbital involvement can impair the functions of cranial nerves III, IV and VI resulting in proptosis, ptosis, pupillary dilatation, orbital cellulitis and loss of vision. Direct penetration and growth of the fungi through the walls of blood vessels can result in thrombosis and extensive tissue necrosis. [57] Hematogenous spread to the cavernous sinus can lead to fatal cavernous sinus thrombosis. [61],[64],[73] Rhinocerebral mucormycosis can also spread by perineural invasion. [74]

Diagnosis

Suspicion of mucormycosis necessitates a CT scan of the maxilla, orbits and brain. In particular, evidence of intracranial brain abscesses and orbital extensions is critical. Sinus and orbital extensions are recognized by membrane or periosteal thickenings as well as bony disruption. [75]

Routine blood studies will show leukocytosis in the 12,000-20,000/ mm 3 range and usually a shift to the left. If the patient is diabetic, a full workup of serum glucose, electrolytes, blood chemistries and blood gases is required. Serological assays for Mucor antigens have been developed. [75]

Histopathologically broad, irregularly shaped, nonseptate hyphae with right angle branching are seen invading the tissue in H and E-stained sections; but are better visualized with PAS or methanamine silver stains. Ideally the biopsy specimen should be obtained from the junction of necrotic and non-necrotic tissue. The organisms are mainly seen within the walls of necrotic blood vessels. [75] Culturing can be done on Sabouraud's glucose agar and sporulation of fungal hyphae within 24-48 hours helps to identify mucor. [76]


   Cryptococcosis Top


0Cryptococcus neoformans and Cryptococcus gattii are commonly considered as the causative agents of cryptococcosis. [34] C. neoformans generally affects immunocompromised hosts whereas C. gattii is isolated more from immunocompetent individuals. [34],[77]

Clinical presentation

C. neoformans infections usually occurs after inhalation of fungal spores from the soil and excreta of birds like pigeons, parrots and canaries. [78] In immunocompetent individuals the infection remains subclinical within the lungs. In the immunocompromised host, the fungus produces rapid disseminated infection involving central nervous system, skin, mucous membranes and many other tissues. [79]

The face, scalp and neck are the common sites of cutaneous lesions, presenting as papules, acne form pustules, abscesses, ulcers, superficial granulomas or sinus tracts. [80] Dissemination may occur from reactivation of dormant disease or a primary infection. [81] The most common clinical presentation is meningo encephalitis. The increased occurrence of cryptococcosis in HIV-infected individuals has been reduced by the implementation of Highly Active Anti Retro viral Therapy (HAART). [81]

Cryptococcosis in oral cavity may arise from hematogenous spread of the infection localized in the lungs of AIDS patients. However, oral cryptococcosis can be the initial presentation of a disseminated infection. [81] Violaceous nodules, swellings or ulcers have been reported on the gingiva, hard and soft palates, pharynx, oral mucosa, tonsillar pillar and in tooth socket after extraction. [82]

Diagnosis

Histopathology varies according to the immunological status of the host. In immunocompetent hosts, typical granulomas are formed at the site of cryptococcal infection, with multinucleated giant cells containing intracytoplasmic cryptococci in budding forms. In immunosuppressed patients, proliferating cryptococci present as extra- and intracellular yeast cells with some budding forms with reactive macrophages, minor lymphocytic and neutrophilic infiltrate. The definitive diagnosis of cryptococcosis is established with periodic acid Schiff (PAS), methanamine silver and mucicarmine-stained preparations. The fungal cytoplasm appears bright magenta by PAS stain and mucicarmine stains the fungal capsule. [81],[83] Culture and assay of serum or cerebrospinal fluid for capsular antigen is useful. [84]


   Geotrichosis Top


Geotrichosis is caused by Geotrichum candidium which is a component of the normal microflora of the skin and the mucosa of the respiratory and digestive tracts. It can also be isolated from vegetables, fruits, soil and plants. [85] Oral lesions are caused by G. candidum and G. capitatum. [86],[87],[88],[89]

Clinical presentation

Geotrichosis can present as pseudomembranes, mucosal ulcerations, edematous and erythematous gingivae. Easily scrapable creamy-white pseudomembranous plaques with an erythematous background can be seen mainly on the tongue, resulting in glossitis and on the cheeks. The most common symptoms are burning pain and impaired swallowing. [90] Angular cheilitis and palatal ulcers appearing similar to the ulcers caused by zygomycosis and aspergillosis have been reported. Palatal ulcers can result in a very aggressive palatine- cerebral condition with poor prognosis. [90],[91]

Diagnosis

Direct examination and staining will reveal multiple septate hyphae with rectangular arthroconidia. But some arthroconidia may have rounded appearance (clavata cells) and may be easily mistaken for Candida. Hence culture is recommended for the accurate diagnosis. [90]

In culture G. candidum and G. capitatum are seen as white, membranous, villous, wet colonies. In chromogenic culture media their villous wet growth with slight pink pigmentation distinguishes them from the major Candida species. [90] Various biochemical tests can also aid the diagnosis; but molecular biology is the most accurate technique for species identification by internal transcriber spacer (rDNA). [86],[92]


   Rhodotorula infection Top


The genus Rhodotorula is a pigmented yeast classified under the family Cryptococcaceae. Three main species are actually known: Rhodotorula glutinis, Rhodotorula minuta and Rhodotorula mucilaginosa. [93] R. mucilaginosa is the current name for the species formerly known as Rhodotorula rubra. Rhodotorula is found in air, soil, lakes, ocean water and dairy products. It may colonize plants, humans and other mammals. [94],[95] Rhodotorula produce moist, smooth to mucoid, glistening, pigmented colonies. Salmon-pink to coral red color of the colony is due to the carotenoid pigment, torularhodin. [96] This pigment blocks certain wavelengths of light which can damage the yeast cell. [94],[95]

Clinical presentation

Rhodotorula can cause meningitis, endocarditis, ventriculitis, peritonitis, fungemia, central venous catheter infection and keratitis. [97] Non-healing oral ulcers and white patches are the reported oral presentations of Rhodotorula infection. [98]

Diagnosis

Gram stain will show Gram-positive round, budding yeast cells of 4-8 μm in diameter with clear halo around them. India ink preparation of the smear will demonstrate encapsulated budding yeast cells. [99]

Rhodotorula are pigmented yeasts easily identified as coral pink, smooth, sometimes reticulate, rugose or corrugated and moist to mucoid yeast-like colony forms when grown on SDA. The germ tube test is negative. Rhodotorula produces urease enzyme and does not ferment carbohydrates. [100]


   Saccharomyces infection Top


Saccharomyces cerevisiae (also known as "baker's yeast" or "brewer's yeast") is widespread in nature and is a commensal inhabiting the gastrointestinal tract of humans, which has an important role in maintaining the normal homeostasis of the lower gastrointestinal tract. [101],[102] S. cerevisiae is now included in some diet or health foods. Fungemia from S. cerevisiae can follow the use of live yeast capsules of Saccharomyces boulardii which are used as probiotics for the prevention and treatment of various diarrheal disorders. [103]

Clinical presentation

Lesions resemble invasive candidiasis due to the presence of choreoretinitis and esophagitis in both conditions. Fever may be present in majority of patients. Deep site involvement with necrosis and granulomatous reaction has also been reported. [104] Intra-oral manifestations include ulcers with associated painful swallowing, dry mouth and burning sensation. [102]

Diagnosis

Direct Gram stain from the swab will show majority of Gram-positive budding yeast cells. The culture will give creamy-white yeast-like growth. The Gram staining from the colony will show budding yeast cells without any capsule. The organism can be identified using corn meal agar and carbohydrate assimilation test. [102]


   Fusariosis Top


Fusarium species are important plant pathogens causing various diseases on cereal grains, occasionally causing infection in animals. [105],[106] In humans, Fusarium species cause both superficial infections (such as keratitis and onychomycosis), allergic diseases and disseminated diseases. [107]

Fusarium solani was most frequent species followed by Fusarium oxysporum and Fusarium verticillioidis and Fusarium moniliforme. [105] Fusarium species are the second-most common mould causing invasive fungal infections in immunocompromised individuals. [108],[109]

Clinical presentation

The clinical presentation of fusariosis depends principally on the immune status of the host and the portal of entry of the infection. [110] The main routes of entry for Fusarium species are the airways and the skin. Risk factors are persistent neutropenia, severe depletion of T- lymphocytes and previous fungal infections. [111] Disseminated infection and skin involvement leading to cellulitis are seen in immunocompromised patients. These lesions may frequently appear as multiple erythematous papules or nodules with central necrosis. [110]

Fusariosis presenting as a necrotic ulceration of the gingiva, extending to the alveolar bone has been reported in a granulocytopenic patient. [112]

Diagnosis

Skin lesions (cellulitis and metastatic lesions) and positive blood cultures for mold can suggest disseminated fusariosis. Due to the dissemination of yeast-like structures, blood cultures are often positive in fusariosis. [113] In histopathology the hyphae are similar to those of Aspergillus species, with hyaline and septate filaments that typically dichotomize in acute and right angles. The finding of hyphae and yeast-like structures together is highly suggestive of fusariosis. [114] From cultures, Fusarium can be identified by the presence of hyaline, banana shaped multicellular macroconidia with a foot cell at the base. [115] But species identification is difficult and needs molecular techniques like PCR. [115]


   Penicilliosis Top


Penicilliosis is caused by Penicillium marneffei which can cause fatal infection in HIV-infected individuals. [116] It is a dimorphic fungus that can exist in mycelia form at 25ºC and yeast form at 37ºC. [117] It was first identified in 1973, as an opportunistic infection in a patient with Hodgkins lymphoma. [118] In South-east Asian countries like Thailand, Penicilliosis is the third-most common opportunistic infection in people with AIDS. [116]

Clinical presentation

Penicilliosis is mostly seen in late HIV infection with CD4+ count less than 100/μL. [119],[120],[121] Inhalation of air-borne conidia is the most common mode of transmission. [122] Most of the patients have fever, weight loss and malaise. Skin manifestation such as subcutaneous abscesses, molluscum contagiosum-like lesions and papule-like ulcers may be present. [123] Respiratory involvement is characterized by productive cough, dyspnea and hemoptysis. [124] Oral lesions include papules, erosions or shallow ulcers covered by yellow necrotic slough which are mainly seen on the palate, gingiva, labial mucosa, tongue and oropharynx. [125]

Diagnosis

The diagnosis of penicilliosis may be made through examination of cytology or biopsy specimens. [126] In fungemia, yeast cells may be seen inside monocytes in peripheral blood smear and are best demonstrated by PAS/methanamine silver stain. [127] Detection of non-budding yeast cells with characteristic central transverse septum is the key to diagnosis which should be confirmed by microbiological culture. [126] isolation of P. maneffei is the gold standard for diagnosis. Culture on SDA at 25ºC for 3 days will give granular colonies with greenish-yellow color and a characteristic red diffusible pigment. [126] In histopathologically occult cases, methanamine silver stain can aid in the diagnosis. [127] Various types of antigen-antibody testing and PCR assay specific to P. marneffei have been developed in research laboratories, but are not widely available. [126]


   Conclusions Top


Fungi are opportunistic infectious agents and most of them are not usually pathogenic. But when they infect an immunocompromised host, can cause a wide range of diseases ranging from superficial to disseminated infections involving the vital internal organs. The outcome of invasive fungal infections depends on various factors such as the clinical condition of the patient, immunological status, pathogenicity and virulence factors of the invading fungal species and the location of the infected area. [128]

The range of patients at risk for invasive fungal infections continues to expand beyond the normal host to encompass patients with acquired immunodeficiency syndrome; diabetes mellitus, those undergoing therapy for cancer and organ transplantation and major surgical procedures. As the population at risk continues to expand, so also does the spectrum of opportunistic fungal pathogens infecting these patients.

Inhalation of spores of these microorganisms is the most common mode of infection in a susceptible host. Hence, prevention of the same would be an excellent prophylactic measure to contain opportunistic fungal infections especially in immunocompromised individuals.

 
   References Top

1.Odds FC, Gow NA, Brown AJ. Fungal virulence studies come of age. Genome Biol 2001;2:REVIEWS 1009.  Back to cited text no. 1
    
2.Pfaller MA. Invasive fungal pathogens: Current epidemiological trends. Clin Infect Dis 2006;43:S3-14.  Back to cited text no. 2
    
3.Segal BH, Romani LR. Invasive aspergillosis in chronic granulomatous disease. Med Mycol 2009:S282-90.  Back to cited text no. 3
    
4.Baskova L, Buchta V. Laboratory diagnostics of invasive fungal infections: An overview with emphasis on molecular approach. Folia Microbiol 2012;57:421-30.  Back to cited text no. 4
    
5.Singh N. Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001;33:1692-6.  Back to cited text no. 5
[PUBMED]    
6.Badiee P, Hashemizadeh Z. Opportunistic invasive fungal infections: Diagnosis and clinical management. Indian J Med Res 2014;139:195-204.  Back to cited text no. 6
[PUBMED]  Medknow Journal  
7.Akpan A, Morgan R. Oral candidiasis. Postgrad Med J 2002;78:455.  Back to cited text no. 7
    
8.Cannon RD, Chaffin WL. Oral colonization by candida albicans. Crit Rev Oral Biol Med 1995;10:359.  Back to cited text no. 8
    
9.Belazi M, Velegraki A, Koussidou-Eremondi T, Andrealis D, Hini S, Arsenis G, et al. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: Prevalence, azole susceptibility profiles and response to antifungal treatment. Oral Microbiol Immunol 2004;19:347.  Back to cited text no. 9
    
10.Odds FC. Candida and candidosis - A review and bibliography. 2 nd ed.vol 1. Bailliere Tindall -WB Saunders London; 1988.  Back to cited text no. 10
    
11.Li L, Redding S, Dongari-Bagtzoglou A. Candida glabrata, an emerging opportunistic pathogen. J Dent Res 2007;86:204.  Back to cited text no. 11
    
12.Richardson MD, Warnock DW. Fungal infections: Diagnosis and management. 3 rd ed.vol 1. Oxford (UK): Blackwell Publishing; 2003.  Back to cited text no. 12
    
13.Meurman JH, Siikala E, Richardson M, Rautemaa R. Non-candida albicans Candida yeasts of the oral cavity. Communicating Current Research and Educational Topics and Trends in Applied Microbiolgy. A Mendez-Vilas (Ed). 2007; 1: 719-731.  Back to cited text no. 13
    
14.Moran GP, Sullivan DJ, Coleman DC. Emergence of non-Candida albicans Candida species as pathogens. In: Candida and candidiasis. 4 th ed.vol 1. Washington: ASM Press; 2002. p. 37-53.  Back to cited text no. 14
    
15.Sullivan DJ, Westernberg TJ, Haynes KA, Bennett DE, Coleman DC. Candida dublieniesis sp. Nov; Phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV infected individuals. Microbiology 1995;141:1507.  Back to cited text no. 15
    
16.Coleman DC, Sullivan DJ, Bennett DE, Moran GP, Barry HJ, Shanley DB. Candidiasis; the emergence of a novel species, Candida dublieniesis. AIDS 1997;11:557.  Back to cited text no. 16
[PUBMED]    
17.Pinjon E, Moran GP, Coleman DC, Sullivan DJ. Azole susceptibility and resistance in Candida dublieniesis. Biochem Soc Trans 2005;33:1210.  Back to cited text no. 17
    
18.Nucci M, Marr KA. Emerging Fungal Diseases. Clin Infect Dis 2005;41:521.  Back to cited text no. 18
    
19.Mardani M, Hanna HA, Girgawy E, Raad I. Nosocomial Candida guilliermondii fungemia in cancer patients. Infect Control Hosp Epidemiol 2000;21:336-7.  Back to cited text no. 19
    
20.Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995;8:462.  Back to cited text no. 20
[PUBMED]    
21.Samaranayke YH, Samaranayke LP. Candida krusei: Biology, epidemiology, pethogenecity and clinical manifestations as an emerging pathogen. J Med Microbiol 1994;41:295.  Back to cited text no. 21
    
22.Viudes A, Peman J, Canton E, Salavert M, Ubeda P, Lopez-Ribot JL, et al. Two cases of fungemia due to Candida lusitaniae and a literature review. Eur J Clin Microbiol Infect Dis 2002;21:294.  Back to cited text no. 22
    
23.Smith PB, Steinbach WJ, Benjamin DK. Neonatal candidiasis. Infect Dis Clin North Am 2005;19:603.  Back to cited text no. 23
    
24.Sarvikivi E, Lyytikainen O, Soll DR, Pujol C, Pfaller MA, Richrdson MA. Emergence of fluconazole resistance in Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 2005;43:2729.  Back to cited text no. 24
    
25.Maenza JR, Merz WG. Candida albicans and related species. In: Jonathan Cohen, William G.Powderly and Gill day. Infectious Diseases, 2 nd ed, vol 1. Saunders; 1998. p. 2313-22.  Back to cited text no. 25
    
26.Epstein JB, Silverman S, Fleischmann J. Oral fungal infections. In: Silverman S, Eversole LR and Truelove EL. Essentials of Oral Medicine, 3 rd ed vol 1. Hamilton (London):BC Decker Inc; 2002. p. 170-9.  Back to cited text no. 26
    
27.Neville BW, Damm DD, Allen CM and Bouquot JE. Oral and Maxillofacial Pathology, 3 rd ed. .Philadelphia: Saunders Company Ltd; 2005.  Back to cited text no. 27
    
28.Samaranayake L. Essential Microbiology for Dentistry. 3 rd ed., vol 1. Edinburgh: Churchill Livingstone; 2006. p. 255, 62-4.  Back to cited text no. 28
    
29.CHROMagar microbiology, Paris, France. Available from: http://chromagar.com [Last accessed on 13 May 2013].  Back to cited text no. 29
    
30.Hospenthal DR, Beckius ML, Floyd KL, Horvath LL, Murray CK. Presumptive identification of Candida species other than C. albicans, C.krusei and C. tropicalis with the chromogenic medium CHROMagar candida. Ann Clin Microbiol Antimicrob 2006;5:1.  Back to cited text no. 30
    
31.Coronado-Castelotte L, Jimenez-Soriano Y. Clinical and microbiological diagnosis of oral candidiasis. J Clin Exp Dent 2013;5:e279-86.  Back to cited text no. 31
    
32.Szabo Z, Toth B, Kovacs M, Kardoz G, Maraz A, Rozgonyi F, et al. Evaluation of the new Micronaut Candida system compared to the API ID 32C method for yeast identification. J Clin Microbiol 2008;46:1824-5.  Back to cited text no. 32
    
33.Verweji PE, Breuker IM, Rijs AJ, Meis JF. Comparative study of seven yeast identification systems. J Clin Pathol 1999;52:271-3.  Back to cited text no. 33
    
34.Krishnan PA. Fungal infections of the oral mucosa. Indian J Dent Res 2012;23:650-9.  Back to cited text no. 34
[PUBMED]  Medknow Journal  
35.Hartwick RW, Batsakis JG. Sinus aspergillosis and allergic fungal sinusitis. Ann Otol Rhinol Laryngol 1991;100:427-30.  Back to cited text no. 35
    
36.Tamgadge AP, Mengi R, Tamgadge S, Bhalerao SS. Chronic invasive aspergillosis of paranasal sinuses: A case report with review of literature. J Oral Maxillofac Pathol 2012;16:460-4.  Back to cited text no. 36
[PUBMED]  Medknow Journal  
37.Marschmeyer G, Ruhnke M. Update on antifungal treatment of invasive Candida and Aspergillus infections. Mycoses 2004;47:263-6.  Back to cited text no. 37
    
38.Scully C, de Almeida OP. Orofacial manifestations of then systemic mycoses. J Oral Pathol Med 1992;21:289-94.  Back to cited text no. 38
    
39.Bathoorn E, Salazar NE, Sepehrkhouy S, Meijer M, de Cock H, Haas P. Involvement of then opportunistic pathogen Aspergillus tubingensis in osteomyelitis of the maxillary bone: A case report. BMC Infect Dis 2013;13:59.  Back to cited text no. 39
    
40.Bajwa SJ, Kulshrestha A. Fungal infections in intensive care unit: Challenges in diagnosis and management. Ann Med Health Sci Res 2013;3:238-44.  Back to cited text no. 40
[PUBMED]  Medknow Journal  
41.Rowe-Jones JM, Meore-Gillon V. Destructive noninvasive paranasal sinus aspergillosis: Component of a spectrum of disease. J Otolaryngol 1994;23:92-6.  Back to cited text no. 41
    
42.Dreizen S, Keating MJ, Beran M. Orofacial fungal infections. Nine pathogens that may invade during chemotherapy. Postgrad Med 1992;91:349-50, 353-44, 357-60.  Back to cited text no. 42
    
43.Benson-Mitchell R, Tolley N, Croft CB, Gallimore A. Aspergillosis of the larynx. J Laryngol Otol 1994;108:883-5.  Back to cited text no. 43
    
44.Myoken Y, Sugata T, Kyo TI, Fujihara M. Pathological features of invasive oral aspergillosis in patients with hematologic malignancies. J Oral Maxillofac Surg 1996;54:263-70.  Back to cited text no. 44
    
45.Emmanuelli JL. Infectious granulomatous diseases of the head and neck. Am J Otolaryngol 1993;14:155-67.  Back to cited text no. 45
[PUBMED]    
46.Chambers MS, Lyzak WA, Martin JW, Lyzak JS, Toth BB. Oral complications associated with aspergillosis in patients with a hematologic malignancy. Presentation and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79:559-63.  Back to cited text no. 46
    
47.Dreizen S, Bodey GP, McCredie KB, Keating MJ. Orofacial aspergillosis in acute leukemia. Oral Surg Oral Med Oral Pathol 1985;59:499-504.  Back to cited text no. 47
[PUBMED]    
48.Sugata T, Myoken Y, Kyo T, Fujihara M. Invasive oral aspergillosis in immunocompromised patients with leukemia. J Oral Maxillofac Surg 1994;52:382-6.  Back to cited text no. 48
    
49.Rossouw DP, Swart JG. Aspergillus fumigatus infection of the maxillary sinus. S Afr Med J 1988;73:47-78.  Back to cited text no. 49
    
50.Ogata Y, Okinaka Y, Takahashi M. Antrolith associated with Aspergillosis of the maxillary sinus: Report of a case. J Oral Maxillofac Surg 1997;55:1339-41.  Back to cited text no. 50
    
51.Napoli JA, Donegan JO. Aspergillosis and necrosis of the maxilla: A case report. J Oral Maxillofac Surg 1991;49:532-4.  Back to cited text no. 51
    
52.Denning DW. Invasive Aspergillosis. Clin Infect Dis 1998;26:781-805.  Back to cited text no. 52
[PUBMED]    
53.Dreizen S. Oral complications of cancer therapies: Description and incidence of oral complications. Monogr Natl Cancer Inst 1990;9:11-5.  Back to cited text no. 53
    
54.Dayananda BC, Vandana R, Rekha K, Kumar GS. Aspergillosis of the maxillary antrum. A case report. J Oral Maxillofac Pathol 2002;1:26-9.  Back to cited text no. 54
    
55.Sapp JP, Eversole LR, Wysocki GP. Contemporary Oral and Maxillofacial Pathology. 2 nd ed., vol 1. Missouri: Mosby-An Affiliate of Elsevier; 2004. p. 207-51.  Back to cited text no. 55
    
56.Regezi JA, Sciubba JJ, Jordan RC, editors. Oral pathology-Clinical Pathologic Correlations. 4 th ed., vol 1. Missouri: Saunders-An Imprint of Elsevier Science; 2003. p. 23-74.  Back to cited text no. 56
    
57.Bakathir AA. Mucormycosis of the jaw after dental extractions: Two case reports. Sultan Qaboos Univ Med J 2006;6:77-82.  Back to cited text no. 57
[PUBMED]    
58.Perusquia-Ortiz AM, Vazquez-Gonzalez D, Bonifaz A. Opportunistic filamentous mycoses: Aspergillosis, mucormycosis, phaehyphomycosis and hyalohyphomycosis. J Dtsch Dermatol Grs 2012;10:611-21.  Back to cited text no. 58
    
59.Auluck A. Maxillary necrosis by mucormycosis. A case report and literature review. Med Oral Patol Oral Cir Bucal 2007;12:E360-4.  Back to cited text no. 59
[PUBMED]    
60.Bouza E, Munoz P, Guinea J. Mucormycosis: An emerging disease? Clin Microbiol Infect 2006;12:7-23.  Back to cited text no. 60
    
61.Sugar AM. Mucormycosis. Clin Infect Dis 1992;14:126-9.  Back to cited text no. 61
    
62.Huang JS, Kok SH, Lee JJ, Hsu WY, Chiang CP, Kuo YS. Extensive maxillary sequestration resulting from mucormycosis. Br J Oral Maxillofac Surg 2005;43:532-4.  Back to cited text no. 62
    
63.McNulty JS. Rhinocerebral mucormycosis: Predisposing factors. Laryngoscope 1982;92:1140-4.  Back to cited text no. 63
[PUBMED]    
64.Kim J, Fortson JK, Cook HE. A fatal outcome from rhinocerebral mucormycosis after dental extractions: A case report. J Oral Maxillofac Surg 2001;59:693-7.  Back to cited text no. 64
    
65.Gale GR, Welch AM. Studies of opportunistic fungi. Inhibition of Rhizopus oryzae by human serum. Am J Med Sci 1961;241:604-8.  Back to cited text no. 65
[PUBMED]    
66.Bauer H, Flanagan JF, Sheldon WH. Experimental cerebral mucormycosis in rabbits with alloxan diabetes. Yale J Biol Med 1955;28:29-32.  Back to cited text no. 66
[PUBMED]    
67.Damante JH, Fleury RN. Oral and rhinocerebral mucormycosis: Case Report. J Oral Maxillofac Surg 1998;56:267-71.  Back to cited text no. 67
    
68.Hadzri MH, Azariman SM, Fauzi AR, Kahairi A. Invasive rhinocerebral mucormycosis with orbital extension in poorly controlled diabetes mellitus. Singapore Med J 2009;50:e107.  Back to cited text no. 68
    
69.Tippu SR, Rahman F, Pilania D. mucormycosis of maxilla - an overview and case report. THE CUSP 2013;10:23-6.  Back to cited text no. 69
    
70.Woo SB, Greenberg MS. Ulcerative, vesiculous and bullous lesions. In: Greenberg MS, editor. Glick Burket's Oral Medicine. 11 th ed.vol 1. BC Decker Inc Hamilton; 2008. p. 74-5.  Back to cited text no. 70
    
71.Cohen SG, Greenberg MS. Rhinomaxillary mucormycosis in kidney transplant patient. Oral Surg 1980;50:33-8.  Back to cited text no. 71
    
72.Jones AC, Bentsen TY, Freedman PD. Mucormycosis of the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1993;75:455-60.  Back to cited text no. 72
    
73.Peterson KL, Wang M, Canalis RF. Rhinocerebral mucormycosis: Evaluation of the disease and treatment options. Laryngoscope 1997;107:855-61.  Back to cited text no. 73
    
74.McLean FM, Ginsberg LE, Stanton CA. Perineural spread of rhinocerebral mucormycosis. Am J Neuroradiol 1996;17:114-6.  Back to cited text no. 74
    
75.Marx RE, Stern D. Oral and maxillofacial pathology; A rationale for diagnosis and treatment. 1 st ed. Vol 1. United Kingdom. Quintessence Publishing Co. Inc; 2006. p. 104-6.  Back to cited text no. 75
    
76.Chayalkulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis; The re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006;25:215-9.  Back to cited text no. 76
    
77.Iatta R, Napoli C, Borghi E, Montagna MT. Rare mycoses of the oral cavity; a literature epidemiologic review. Oral Surg Oral Med Oral Pathol Oral Radiol End 2009;108:647-55.  Back to cited text no. 77
    
78.Cafarchia C, Rmoito D, Iatta R. Role of birds of prey as carriers and spreaders of C. neoformans and other zoonotic yeasts. Med Mycol 2006;44:485-92.  Back to cited text no. 78
    
79.Rippon JW. Medical Mycology. 3 rd ed, vol 1. Philadelphia: WB Saunders; 1988.  Back to cited text no. 79
    
80.Moore M. Cryptococcosis with cutaneous manifestations; four cases with review of published reports. J Invest Dermatol 1957;28:159-82.  Back to cited text no. 80
    
81.Delgado WA, Leon ER. 14 th International Congress IAOP/AAOMP Clinical Pathology Conference Case 6. Head Neck Pathol 2008;2:298-301.  Back to cited text no. 81
    
82.Cawley EP, Grekin RH, Curtis AC. Torulosis: A review of the cutaneous and adjoining mucous membrane manifestations. J Invest Dermatol 1950;14:327-44.  Back to cited text no. 82
    
83.Shibuya K, Hirata A, Omuta J, Sugamata M, Katori S, Saito N, et al. Granuloma and Cryptococcosis. J Infect Chemother 2005;11:115-22.  Back to cited text no. 83
    
84.Samaranayake LP, Leung WK, Jin L. Oral mucosal fungal infections. Periodontology 2000. 2009;49:39-59.  Back to cited text no. 84
    
85.Pottier I, Gente S, Vernoux JP. Safety assessment of diary microorganisms: Geotrichum candidum. Int J Food Microbiol 2008;126:327-32.  Back to cited text no. 85
    
86.Hattori H, Inoue C, Tomita Y, Kanbe T. A case of oral Geotrichosis caused by Geotrichum candidum in an old patient. Jpn J Infect Dis 2007;60:300-1.  Back to cited text no. 86
    
87.Heinic GS, Greenspan D. Oral Geotrichum candidum infection associated with HIV infection, a case report. Oral Surg Oral Med Oral Pathol 1992;73:726-8.  Back to cited text no. 87
    
88.Samaranayake LP. Oral mycoses in HIV infection. Oral Surg Oral Med Oral Pathol Oral Radiol End 1992;73:171-80.  Back to cited text no. 88
    
89.Listemann H, Schonrock-Nalbusi P, Kuse R. Geotrichosis of oral mucosa. Mycoses 1996;39:289-91.  Back to cited text no. 89
    
90.Bonifaz A, Gonzalez DZ, Macias B, Parades-Farrera F, Hernandez MA, Araiza J. Oral geotrichosis: Report of 12 cases. J Oral Sci 2010;52:477-83.  Back to cited text no. 90
    
91.Bonifaz A, Macias B, Parades-Farrera F, Arias P, Ponce RM, Araiza J. Palatal zygomycosis; Experience of 21 cases. Oral Dis 2008;14:569-74.  Back to cited text no. 91
    
92.Henrich TJ, Marty FM, Milner DA. Disseminated G. Candidum infection in patient with relapsed acute myelogenous leukemia following allogenic stem cell transplantation with review of literature. Transpl Infect Dis 2009;11:458-62.  Back to cited text no. 92
    
93.Lanzafame M, De Chechhi G, Parinello A. Rhodotorula glutinis related meningitis. J Clin Microbiol 2001;39:410.  Back to cited text no. 93
    
94.Available from: http://doctorfungus.org/the fungi rhodotorula- mucilaginosa.htm [Last accessed on 12 Feb 2013].  Back to cited text no. 94
    
95.De Hoog, Guarro JG. Atlas of clinical fungi. 2 nd ed., vol 1. Centralbureau voor Schimmelcultures: The Netherlands; 2000.  Back to cited text no. 95
    
96.Lo Re V III, Fishman NO, Nachamkin I. Recurrent catheter related Rhodotorula rubra infection. Clin Microbiol Infect 2003;9:897-900.  Back to cited text no. 96
    
97.Pamidimukkala U, Challa S, Lakshmi V. Sepsis and meningoencephalitis due to Rhodotorula glutinis in a patient with systemic lupus erythematosus, diagnosed at autopsy. Neurol India 2007;55:304-7.  Back to cited text no. 97
[PUBMED]  Medknow Journal  
98.Kaur R, Wadhwa A, Agarwal S. Rhodotorula mucilaginosa; an unusual cause of oral ulcers in AIDS patients. AIDS 2007;21:1068-9.  Back to cited text no. 98
    
99.Shinde RS, Mantur BG, Patil G, Parande MV, Parande AM. Meningitis due to Rhodotorula lutinis in an HIV infected patient. Indian J Med Microbiol 2008;26:375-97.  Back to cited text no. 99
[PUBMED]  Medknow Journal  
100.Anaissie EJ, McGinnis MR, Pfaller MA. Clinical mycology. 2 nd ed., vol 1. Churchill Livingstone; Philadelphia, 2003.  Back to cited text no. 100
    
101.Kwon- Chung J, Bennett JE. Medical Mycology. 1 st ed., vol 1. Philadelphia: Lea and Febinger; 1992.  Back to cited text no. 101
    
102.Wadhwa A, Kaur R, Bhalla P. Saccharomyces cerevisiae as a cause of oral thrush and diarrhoea in an HIV/AIDS patient. Trop Gastroenterol 2010;31:227-9.  Back to cited text no. 102
    
103.Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal disease with the use of probiotics. Am J Clin Nutr 2001;73 Suppl 2:430-6S.  Back to cited text no. 103
    
104.Jensen DP, Smith DL. Fever of unknown origin secondary to brewer's yeast ingestion. Arch Intern Med 1976;136:332-3.  Back to cited text no. 104
    
105.Nelson PE, Dignani MC, Annaissie EJ. Taxonomy, biology and clinical aspects of Fusarium species. Clin Microbiol Rev 1994;7:479-504.  Back to cited text no. 105
    
106.Evans J, Levesque D, de LA, Jensen HE. Intracranial fusariosis: A novel cause of fungal meningoencephalitis in a dog. Vet Pathol 2004;41:510-4.  Back to cited text no. 106
    
107.Nucci M, Annaisie E. Cutaneous infection by Fusarium species in healthy and immunocompromised patients. Clin Infect Dis 2002;35:909-20.  Back to cited text no. 107
    
108.Boutati EI, Annaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer centre and implications of management. Blood 1997;90:999-1008.  Back to cited text no. 108
    
109.Walsch TJ, Groll AH. Emerging fungal infections. Transpl Infect Dis 1999;1:247-61.  Back to cited text no. 109
    
110.Nucci M, Annaisie E. Fusarium Infections in Immunocompromised Patients. Clin Microbiol Rev 2007;20:695-704.  Back to cited text no. 110
    
111.Huprikar S, Shoham S. Emerging fungal infections in solid organ transplantation. Am J Transplant 2013;13:262-71.  Back to cited text no. 111
    
112.Myoken Y, Sugata T, Kyo T, Fujihara M. Oral Fusarium infection in a granulocytopenic patient with acute myelogenous leukemia: A case report. J Oral Pathol Med 1995;24:237-40.  Back to cited text no. 112
    
113.Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces and Acremonium species by histopathology. Am J Clin Pathol 1998;109:45-54.  Back to cited text no. 113
    
114.Hayden RT, Isotalo PA, Parrett T, Wolk DM, Qian X, Roberts GD, et al. In situ hybridization for the differentiation of Aspergillus, Fusarium and Pseudallescheria species in tissue sections. Diagn Mol Pathol 2003;12:21-6.  Back to cited text no. 114
    
115.Healy M, Reece K, Walton D, Huong J, Frye S, Raad II. Use of Diversi Lab system for species and strain differentiation of Fusarium species isolates. J Clin Microbiol 2005;43:5278-80.  Back to cited text no. 115
    
116.Dahiya P. Penicilliosis in an HIV positive individual. Indian J Sex Trans Dis AIDS 2012;33:38-40.  Back to cited text no. 116
    
117.Segretain G. Penicillium marneffei agent of mycosis of reticuloendothelial system. Mycopathologia 1959;11:327-53.  Back to cited text no. 117
    
118.Tlamcani Z, Er-rami M. Fungal opportunistic infection: Common and emerging fungi in immunocompromised patients. J Immunol Tech Infect Dis 2013;2:1-5.  Back to cited text no. 118
    
119.Sapparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillosis in Southeast Asia. Lancet 1994;344:110-3.  Back to cited text no. 119
    
120.Wu TC, Chan JW, Ng CK, Tsang DN, Lee MP, Li PC. Clinical presentations and outcomes of Penicillium marneffei infections: A series from 1994 to 2004. Hong Kong Med J 2008;14:103-9.  Back to cited text no. 120
    
121.Antinori S, Gianelli E, Bonaccorso C, Ridolfo AL, Croce F, Sollima S, et al. Disseminated Penicillium marneffei infection in HIV positive Italian patient and review of cases reported outside epidemic regions. J Travel Med 2006;13:181-8.  Back to cited text no. 121
    
122.Chitasombat M, Sapparatpinyo K. Penicillium marneffei infection in immunocompromised host. Curr Fungal Infect Rep 2013;7:44-50.  Back to cited text no. 122
    
123.Cooper CR Jr, McGinnis MR. Pathology of Penicillium marneffei; an emerging acquired immunodeficiency syndrome- related pathogen. Arch Pathol Lab Med 1997;89:798-804.  Back to cited text no. 123
    
124.Deesomchok A, Tanprawate S. A 12 case series of Penicillium marneffei pneumonia. J Med Assoc Thailand 2006;89:441-7.  Back to cited text no. 124
    
125.Nittayanantha W. Penicilliosis marneffei another AIDS defining illness in Southeast Asia. Oral Dis 1999;5:286-93.  Back to cited text no. 125
    
126.Wong SY, Wong KF. Penicillium marneffei infection in AIDS. Pathol Res Int Volume 2011;2011:764293.  Back to cited text no. 126
    
127.Wong KF. Marrow penicilliosis, a readily missed diagnosis. Am J Clin Pathol 2010;134:214-8.  Back to cited text no. 127
    
128.Ramana KV, Kandi S, Bharatkumar PV, Sharada CH, Rao R, Mani R, et al. Invasive fungal infections: A comprehensive review. Am J Infect Dis Microbiol 2013;1:64-9.  Back to cited text no. 128
    




 

Top
Print this article  Email this article
            

    

 
   Search
 
  
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Article in PDF (532 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
   Aspergillosis
   Mucormycosis
   Cryptococcosis
   Geotrichosis
    Rhodotorula infe...
    Saccharomyces in...
   Fusariosis
   Penicilliosis
   Conclusions
    Candidiasis due ...
    References

 Article Access Statistics
    Viewed3534    
    Printed41    
    Emailed0    
    PDF Downloaded776    
    Comments [Add]    

Recommend this journal

Journal of Oral and Maxillofacial Pathology | Published by Wolters Kluwer - Medknow
Online since 15th Aug, 2007